It’s been a pretty great week for Editas Medicine, Inc. (NASDAQ:EDIT) shareholders, with its shares surging 11% to US$24.71 in the week since its latest quarterly results. Revenues of US$5.7m fell short of estimates by 15%, but statutory losses were tightly controlled, with the per-share loss of US$0.69 being 12% smaller than consensus predictions. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we’ve aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Editas Medicine after the latest results.
View our latest analysis for Editas Medicine
Following last week’s earnings report, Editas Medicine’s seven analysts are forecasting 2020 revenues to be US$24.2m,